EUCTR2010-024537-23-PL进行中（未招募）1 期
A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in HIV Infected, Antiretroviral, Naive and Experienced Pediatric Subjects from 3 Months to Less Than 11 YearsPediatric Atazanavir International Clinical Evaluation: the PRINCE II studyRevised Protocol Number 04, incorporates amendment 07 and Administrative letter 01+ Site Specific Amendment 06 (03-May-2012) - PRINCE II
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Confirmed HIV 1 infection diagnosed by protocol criteria
- •Screening HIV RNA = 1000 copies/mL
- •= 3 months to < 11 years of age at time of first treatment
- •antiretroviral naive or experienced
- •all subjects must have genotypic sensitivity at screening to ATV and at least 2 NRTIs. NRTIs must be approved for pediatric use at the local country.
- •antiretroviral-experienced subjects must also have documented phenotypic sensitivity at screening to ATV (Fold Change in susceptibility < 2.2) and to at least 2 NRTIs that are approved in their country
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 95
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Experienced subjects who received ATV or ATV/RTV at any time prior to study enrollment or who have prior history of 2 or more PI failures
- •Antiretroviral-naïve or experienced HIV-1 infected patients with contraindication to study medications
- •Cardiac rhythm abnormalities
- •Need for Tenofovir
- •Weight < 5kg or =35kg
- •> Grade 2 AST/ALT
- •Coinfection with either HBV or HCV
- •Any active CDC Category C clinical condition
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid in HIV Infected, Antiretroviral, Naive and Experienced Pediatric Subjects From 3 Months to Less Than 11 Years.EUCTR2010-024537-23-GBBristol Myers Squibb International Corporation160
进行中（未招募）
1 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid in HIV Infected, Antiretroviral, Naive and Experienced Pediatric Subjects Greater Than or Equal to 3 Months to Less Than 8 Years. Revised Protocol 01, incorporating protocol amendment 02EUCTR2010-024537-23-ESBristol Myers Squibb International Corporation75
进行中（未招募）
不适用
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid in HIV Infected, Antiretroviral, Naive and Experienced Pediatric Subjects From 3 Months to Less Than 11 Years.HIV in paediatric populationMedDRA version: 14.1Level: LLTClassification code 10020172Term: HIV infection NOSSystem Organ Class: 100000004862EUCTR2010-024537-23-Outside-EU/EEABristol Myers Squibb International Corporation95
进行中（未招募）
2 期
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I study)RBR-3vmkt2Bristol-Myers Squibb
进行中（未招募）
不适用
Safety Sudy of Atazanavir Capsules in the Treatment of HIV in Patients Ages 6 - 18 YearsHIV in paediatric populationEUCTR2011-003300-21-Outside-EU/EEABristol-Myers Squibb Company113